Cardinal Health, Inc.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, MCK has a market cap of 89.10B. Regarding current trading prices, CAH is priced at $151.70, while MCK trades at $710.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas MCK's P/E ratio is 32.57. In terms of profitability, CAH's ROE is -0.50%, compared to MCK's ROE of -1.15%. Regarding short-term risk, CAH is less volatile compared to MCK. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, COR has a market cap of 56.37B. Regarding current trading prices, CAH is priced at $151.70, while COR trades at $290.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas COR's P/E ratio is 41.29. In terms of profitability, CAH's ROE is -0.50%, compared to COR's ROE of +1.85%. Regarding short-term risk, CAH is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ABC has a market cap of 36.15B. Regarding current trading prices, CAH is priced at $151.70, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ABC's P/E ratio is 21.92. In terms of profitability, CAH's ROE is -0.50%, compared to ABC's ROE of +1.72%. Regarding short-term risk, CAH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, SHPMY has a market cap of 8.49B. Regarding current trading prices, CAH is priced at $151.70, while SHPMY trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas SHPMY's P/E ratio is 9.69. In terms of profitability, CAH's ROE is -0.50%, compared to SHPMY's ROE of +0.06%. Regarding short-term risk, CAH is less volatile compared to SHPMY. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, SHPMF has a market cap of 8.13B. Regarding current trading prices, CAH is priced at $151.70, while SHPMF trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas SHPMF's P/E ratio is 10.47. In terms of profitability, CAH's ROE is -0.50%, compared to SHPMF's ROE of +0.06%. Regarding short-term risk, CAH is more volatile compared to SHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, HSIC has a market cap of 8.12B. Regarding current trading prices, CAH is priced at $151.70, while HSIC trades at $66.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas HSIC's P/E ratio is 21.72. In terms of profitability, CAH's ROE is -0.50%, compared to HSIC's ROE of +0.11%. Regarding short-term risk, CAH is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, SHTDY has a market cap of 8.04B. Regarding current trading prices, CAH is priced at $151.70, while SHTDY trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas SHTDY's P/E ratio is 6.72. In terms of profitability, CAH's ROE is -0.50%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, CAH is less volatile compared to SHTDY. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, SHTDF has a market cap of 7.64B. Regarding current trading prices, CAH is priced at $151.70, while SHTDF trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas SHTDF's P/E ratio is 6.45. In terms of profitability, CAH's ROE is -0.50%, compared to SHTDF's ROE of +0.06%. Regarding short-term risk, CAH is less volatile compared to SHTDF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, CAKFY has a market cap of 5.37B. Regarding current trading prices, CAH is priced at $151.70, while CAKFY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, CAH's ROE is -0.50%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, CAH is more volatile compared to CAKFY. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, AMFPF has a market cap of 4.73B. Regarding current trading prices, CAH is priced at $151.70, while AMFPF trades at $21.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas AMFPF's P/E ratio is 28.77. In terms of profitability, CAH's ROE is -0.50%, compared to AMFPF's ROE of +0.13%. Regarding short-term risk, CAH is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, PBH has a market cap of 4.01B. Regarding current trading prices, CAH is priced at $151.70, while PBH trades at $81.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas PBH's P/E ratio is 19.01. In terms of profitability, CAH's ROE is -0.50%, compared to PBH's ROE of +0.12%. Regarding short-term risk, CAH is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, GALNF has a market cap of 3.75B. Regarding current trading prices, CAH is priced at $151.70, while GALNF trades at $75.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas GALNF's P/E ratio is 20.23. In terms of profitability, CAH's ROE is -0.50%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, CAH is more volatile compared to GALNF. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, MAHLY has a market cap of 3.40B. Regarding current trading prices, CAH is priced at $151.70, while MAHLY trades at $16.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas MAHLY's P/E ratio is 10.03. In terms of profitability, CAH's ROE is -0.50%, compared to MAHLY's ROE of +0.06%. Regarding short-term risk, CAH is more volatile compared to MAHLY. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, MEPDF has a market cap of 3.08B. Regarding current trading prices, CAH is priced at $151.70, while MEPDF trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas MEPDF's P/E ratio is 8.97. In terms of profitability, CAH's ROE is -0.50%, compared to MEPDF's ROE of +0.08%. Regarding short-term risk, CAH is less volatile compared to MEPDF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, PDCO has a market cap of 2.77B. Regarding current trading prices, CAH is priced at $151.70, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas PDCO's P/E ratio is 20.48. In terms of profitability, CAH's ROE is -0.50%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, CAH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ALFRY has a market cap of 2.44B. Regarding current trading prices, CAH is priced at $151.70, while ALFRY trades at $13.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ALFRY's P/E ratio is 12.90. In terms of profitability, CAH's ROE is -0.50%, compared to ALFRY's ROE of +0.05%. Regarding short-term risk, CAH is more volatile compared to ALFRY. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ARHCF has a market cap of 2.27B. Regarding current trading prices, CAH is priced at $151.70, while ARHCF trades at $11.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, CAH's ROE is -0.50%, compared to ARHCF's ROE of +0.05%. Regarding short-term risk, CAH is more volatile compared to ARHCF. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, SZUKF has a market cap of 1.72B. Regarding current trading prices, CAH is priced at $151.70, while SZUKF trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, CAH's ROE is -0.50%, compared to SZUKF's ROE of +0.04%. Regarding short-term risk, CAH is more volatile compared to SZUKF. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, IUSDF has a market cap of 1.66B. Regarding current trading prices, CAH is priced at $151.70, while IUSDF trades at $23.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas IUSDF's P/E ratio is 30.05. In terms of profitability, CAH's ROE is -0.50%, compared to IUSDF's ROE of +0.12%. Regarding short-term risk, CAH is less volatile compared to IUSDF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, GRDN has a market cap of 1.62B. Regarding current trading prices, CAH is priced at $151.70, while GRDN trades at $25.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas GRDN's P/E ratio is -14.50. In terms of profitability, CAH's ROE is -0.50%, compared to GRDN's ROE of -1.16%. Regarding short-term risk, CAH is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, MEDOF has a market cap of 1.28B. Regarding current trading prices, CAH is priced at $151.70, while MEDOF trades at $50.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, CAH's ROE is -0.50%, compared to MEDOF's ROE of +0.03%. Regarding short-term risk, CAH is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ARRJF has a market cap of 836.17M. Regarding current trading prices, CAH is priced at $151.70, while ARRJF trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ARRJF's P/E ratio is 18.06. In terms of profitability, CAH's ROE is -0.50%, compared to ARRJF's ROE of +0.06%. Regarding short-term risk, CAH is less volatile compared to ARRJF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, OMI has a market cap of 593.70M. Regarding current trading prices, CAH is priced at $151.70, while OMI trades at $7.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas OMI's P/E ratio is -1.62. In terms of profitability, CAH's ROE is -0.50%, compared to OMI's ROE of -0.45%. Regarding short-term risk, CAH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, WGRX has a market cap of 235.83M. Regarding current trading prices, CAH is priced at $151.70, while WGRX trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas WGRX's P/E ratio is -30.27. In terms of profitability, CAH's ROE is -0.50%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, CAH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ZYXI has a market cap of 61.38M. Regarding current trading prices, CAH is priced at $151.70, while ZYXI trades at $2.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ZYXI's P/E ratio is -8.46. In terms of profitability, CAH's ROE is -0.50%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, CAH is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, GEG has a market cap of 53.85M. Regarding current trading prices, CAH is priced at $151.70, while GEG trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas GEG's P/E ratio is -190.00. In terms of profitability, CAH's ROE is -0.50%, compared to GEG's ROE of +0.00%. Regarding short-term risk, CAH is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, HX has a market cap of 53.37M. Regarding current trading prices, CAH is priced at $151.70, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas HX's P/E ratio is -1.84. In terms of profitability, CAH's ROE is -0.50%, compared to HX's ROE of -0.04%. Regarding short-term risk, CAH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, EXHI has a market cap of 15.06M. Regarding current trading prices, CAH is priced at $151.70, while EXHI trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas EXHI's P/E ratio is N/A. In terms of profitability, CAH's ROE is -0.50%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, CAH is more volatile compared to EXHI. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, NSVGF has a market cap of 8.48M. Regarding current trading prices, CAH is priced at $151.70, while NSVGF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, CAH's ROE is -0.50%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, CAH is less volatile compared to NSVGF. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ENMI has a market cap of 7.66M. Regarding current trading prices, CAH is priced at $151.70, while ENMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ENMI's P/E ratio is -0.20. In terms of profitability, CAH's ROE is -0.50%, compared to ENMI's ROE of +0.51%. Regarding short-term risk, CAH is less volatile compared to ENMI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, RDGT has a market cap of 6.41M. Regarding current trading prices, CAH is priced at $151.70, while RDGT trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas RDGT's P/E ratio is -0.33. In terms of profitability, CAH's ROE is -0.50%, compared to RDGT's ROE of N/A. Regarding short-term risk, CAH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, PDRX has a market cap of 4.26M. Regarding current trading prices, CAH is priced at $151.70, while PDRX trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas PDRX's P/E ratio is 2.56. In terms of profitability, CAH's ROE is -0.50%, compared to PDRX's ROE of -0.07%. Regarding short-term risk, CAH is more volatile compared to PDRX. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, KOSK has a market cap of 3.98M. Regarding current trading prices, CAH is priced at $151.70, while KOSK trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas KOSK's P/E ratio is -0.18. In terms of profitability, CAH's ROE is -0.50%, compared to KOSK's ROE of -0.13%. Regarding short-term risk, CAH is less volatile compared to KOSK. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, ITNS has a market cap of 533194.00. Regarding current trading prices, CAH is priced at $151.70, while ITNS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas ITNS's P/E ratio is -0.03. In terms of profitability, CAH's ROE is -0.50%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, CAH is less volatile compared to ITNS. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, PHRX has a market cap of 5171.00. Regarding current trading prices, CAH is priced at $151.70, while PHRX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas PHRX's P/E ratio is N/A. In terms of profitability, CAH's ROE is -0.50%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, CAH is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, CHME has a market cap of 2380.00. Regarding current trading prices, CAH is priced at $151.70, while CHME trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas CHME's P/E ratio is N/A. In terms of profitability, CAH's ROE is -0.50%, compared to CHME's ROE of +0.04%. Regarding short-term risk, CAH is more volatile compared to CHME. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, MLTO has a market cap of 1700.00. Regarding current trading prices, CAH is priced at $151.70, while MLTO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas MLTO's P/E ratio is -0.00. In terms of profitability, CAH's ROE is -0.50%, compared to MLTO's ROE of N/A. Regarding short-term risk, CAH is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, TGVN has a market cap of 120.00. Regarding current trading prices, CAH is priced at $151.70, while TGVN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas TGVN's P/E ratio is -0.00. In terms of profitability, CAH's ROE is -0.50%, compared to TGVN's ROE of N/A. Regarding short-term risk, CAH is more volatile compared to TGVN. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.

CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAH stands at 36.65B. In comparison, CVET comparison data is unavailable. Regarding current trading prices, CAH is priced at $151.70, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAH currently has a P/E ratio of 23.78, whereas CVET's P/E ratio is -69.97. In terms of profitability, CAH's ROE is -0.50%, compared to CVET's ROE of -0.06%. Regarding short-term risk, CAH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.